Ocular Therapeutix™ Strengthens Management Team with the Appointment of Andy Hurley as Chief Commercial Officer

BEDFORD, Mass--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Andy Hurley to the newly created position of chief commercial officer, effective immediately. In this role, Mr. Hurley will be responsible for leading Ocular’s commercial organization, focusing on effective execution of potential future product launc